The UK’s position as a world leader within the global Genomics industry could be under threat thanks to uncertainties about the future working status of EU nationals in this country.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
Head of the FDA, Scott Gottlieb has suggested some ways in which pharma giants could rethink their business models, to help unproductive drugmakers.
Experts have revealed that cut-price copies of an expensive Roche biotech drug for blood cancer have taken 80% of the British market since launching last year, saving the healthcare system £80 million a year.
Going against industry trend of backing out of the neuroscience field, is Celgene, who is about to put down a potential $2.2 million to gain options on three Prothena drug candidates.
Healthcare tech startup Theranos was riding high back in 2014. But when a reporter raised questions, its media reps circled the wagons.
Chinese pharmaceutical companies are proving their place in the US generic drugs market, with a rising number of approvals for copycat medicines almost doubling in the past year.
FDA Commissioner, Scott Gottlieb has critiqued health insurers, as he homes in on the increasingly popular target of rebates in the drug pricing debate.
Novartis is preparing to make some big changes to its structure following the departure of its operations chief, and a desire to aim for big digital things.